Quarterly ResultAug 12, 2026, 04:26 PM
ArriVent BioPharma Q2 Net Loss $49.9M; Cash $154.7M
AI Summary
ArriVent BioPharma reported a net loss of $49.9 million for the second quarter of 2026, an increase from $31.4 million in the same period last year. However, the year-to-date net loss for the first half of 2026 decreased to $93.2 million from $95.8 million in the prior year. The company significantly increased its cash and cash equivalents to $154.7 million and total assets to $394.7 million, primarily driven by $141.0 million in net cash from financing activities. ArriVent BioPharma continues to incur losses as a clinical-stage biopharmaceutical company, with an accumulated deficit of $497.9 million, but states it has sufficient liquidity to sustain operations for at least the next twelve months.
Key Highlights
- Net loss for Q2 2026 was $49.9 million, compared to $31.4 million in Q2 2025.
- Year-to-date net loss for H1 2026 was $93.2 million, down from $95.8 million in H1 2025.
- Cash and cash equivalents increased to $154.7 million at June 30, 2026, from $45.5 million at December 31, 2025.
- Total assets grew to $394.7 million at June 30, 2026, from $333.2 million at December 31, 2025.
- Research and development expenses were $42.3 million in Q2 2026, up from $27.7 million in Q2 2025.
- General and administrative expenses were $10.4 million in Q2 2026, up from $5.9 million in Q2 2025.
- Net cash provided by financing activities for H1 2026 was $141.0 million, up from $81.9 million in H1 2025.
- Accumulated deficit reached $497.9 million as of June 30, 2026.
Price Impact
More from AVBP